Gr. Sarantis Valuation
Is SAR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of SAR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: SAR (€11.38) wird unter unserer Schätzung des Fair Value (€11.61) gehandelt.
Deutlich unter dem Marktwert: SAR unter dem beizulegenden Zeitwert gehandelt wird, jedoch nicht um einen signifikanten Betrag.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SAR?
Other financial metrics that can be useful for relative valuation.
| What is SAR's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | €739.17m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.5x |
| Enterprise Value/EBITDA | 12.7x |
| PEG Ratio | 1.7x |
Price to Earnings Ratio vs Peers
How does SAR's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 18x | ||
605009 Hangzhou Haoyue Personal Care | 13x | 20.5% | CN¥6.1b |
1707 Grape King Bio | 16.4x | 7.5% | NT$23.8b |
A192820 Cosmax | 25.6x | 30.6% | ₩1.5t |
MARICO Marico Bangladesh | 17.2x | 10.5% | ৳77.3b |
SAR Gr. Sarantis | 18.8x | 11.3% | €739.2m |
Price-To-Earnings gegen Gleichaltrige: SAR ist auf der Grundlage des Price-To-Earnings Verhältnisses (19.7x) im Vergleich zum Durchschnitt der Vergleichsgruppe (16.5x) teuer.
Price to Earnings Ratio vs Industry
How does SAR's PE Ratio compare vs other companies in the European Personal Products Industry?
Price-To-Earnings gegen Industrie: SAR ist aufgrund seines Price-To-Earnings Verhältnisses (16x) im Vergleich zum European Personal Products Branchendurchschnitt (26.2x) ein guter Wert.
Price to Earnings Ratio vs Fair Ratio
What is SAR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 18.8x |
| Fair PE Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Earnings Fair Ratio von SAR für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €11.38 | €9.48 -16.7% | 28.8% | €14.50 | €6.40 | n/a | 5 |
| Mar ’25 | €9.48 | €8.50 -10.3% | 15.7% | €10.60 | €6.40 | n/a | 5 |
| Feb ’25 | €8.76 | €8.50 -3.0% | 15.7% | €10.60 | €6.40 | n/a | 5 |
| Jan ’25 | €8.38 | €7.98 -4.8% | 11.6% | €8.70 | €6.40 | n/a | 4 |
| Dec ’24 | €8.00 | €7.98 -0.3% | 11.6% | €8.70 | €6.40 | n/a | 4 |
| Nov ’24 | €7.90 | €7.98 +0.9% | 11.6% | €8.70 | €6.40 | n/a | 4 |
| Oct ’24 | €7.35 | €7.98 +8.5% | 11.6% | €8.70 | €6.40 | n/a | 4 |
| Sep ’24 | €7.75 | €7.35 -5.2% | 8.7% | €8.20 | €6.40 | n/a | 4 |
| Aug ’24 | €7.72 | €7.35 -4.8% | 8.7% | €8.20 | €6.40 | n/a | 4 |
| Jul ’24 | €7.48 | €7.35 -1.7% | 8.7% | €8.20 | €6.40 | n/a | 4 |
| Jun ’24 | €7.47 | €7.30 -2.3% | 10.1% | €8.20 | €6.40 | n/a | 3 |
| May ’24 | €7.18 | €7.30 +1.7% | 10.1% | €8.20 | €6.40 | n/a | 3 |
| Apr ’24 | €6.83 | €7.30 +6.9% | 10.1% | €8.20 | €6.40 | €11.74 | 3 |
| Mar ’24 | €7.32 | €7.30 -0.3% | 10.1% | €8.20 | €6.40 | €9.48 | 3 |
| Feb ’24 | €7.50 | €7.30 -2.7% | 10.1% | €8.20 | €6.40 | €8.76 | 3 |
| Jan ’24 | €6.49 | €7.23 +11.5% | 10.2% | €8.20 | €6.40 | €8.38 | 3 |
| Dec ’23 | €6.48 | €7.23 +11.6% | 10.2% | €8.20 | €6.40 | €8.00 | 3 |
| Nov ’23 | €6.30 | €7.78 +23.4% | 11.0% | €8.70 | €6.40 | €7.90 | 4 |
| Oct ’23 | €6.09 | €7.78 +27.7% | 11.0% | €8.70 | €6.40 | €7.35 | 4 |
| Sep ’23 | €6.25 | €8.48 +35.6% | 8.1% | €9.50 | €7.80 | €7.75 | 4 |
| Aug ’23 | €6.96 | €8.48 +21.8% | 8.1% | €9.50 | €7.80 | €7.72 | 4 |
| Jul ’23 | €6.54 | €8.48 +29.6% | 8.1% | €9.50 | €7.80 | €7.48 | 4 |
| Jun ’23 | €7.18 | €8.70 +21.2% | 6.5% | €9.50 | €7.90 | €7.47 | 4 |
| May ’23 | €7.24 | €8.70 +20.2% | 6.5% | €9.50 | €7.90 | €7.18 | 4 |
| Apr ’23 | €7.30 | €8.70 +19.2% | 7.5% | €9.50 | €7.90 | €6.83 | 3 |
Analysten-Prognose: Das Kursziel ist niedriger als der aktuelle Aktienkurs.